June 4, 2018
Current HER2 tests help predict which breast cancer patients will respond to HER2-targeted therapies, but sometimes these tests provide unclear results. An Expert Panel of pathologists and cancer researchers, including Dr. John Bartlett from OICR, recently published revised clinical practice guidelines for HER2 testing in breast cancer to help improve clarity of HER2 test results.
January 12, 2018
Endocrine therapy uses hormone antagonists to greatly reduce the risk of disease recurrence in women with early-stage, estrogen-receptor (ER) positive breast cancer. However, the treatment can come with severe side effects. Around 30 per cent of women stop taking the therapy after three years largely due to these negative impacts. Usually patients receive the hormone therapy for five years following initial treatment (e.g., chemotherapy, surgery), but it can also be taken longer-term. A central question facing patients and clinicians is how to balance, in their decision making, the side effects of long-term treatment with the potential reduction in recurrence risk. In short, they want to know: ‘is it worth it?’
September 6, 2017
OICR’s Tissue Portal is a new central entry and exit point for human tissue derived samples handled at OICR. This will serve as a gateway for tissue-based research projects to access over 100 services and resources at OICR being made available through the OICR Collaborative Research Resources on a cost-sharing basis. The Tissue Portal will standardize and streamline the storage, processing and distribution of samples for collaborative research studies at OICR.
April 13, 2017
Breast cancer is the most common form of cancer amongst women in Canada and worldwide, but despite its prevalence, a group of researchers believes that it should often be treated as a rare disease. Doing so would change clinical approaches and improve treatment for patients.
September 19, 2016
Dr. Rebecca Tamarchak discusses the launch of OICR’s new Collaborative Research Resources Directory, how it works, and plans for its development in the future.
Over the past decade, OICR has established state-of-the-art Technology Programs in molecular pathology and diagnostic development, genomics, informatics, medicinal chemistry and imaging, which are translating promising cancer discoveries into products, services and policies that improve cancer prevention and care for patients.